(3) Indication of any tests prescribed under §§610.40 and 640.5(a), (b), or (c) of this chapter not completed before shipment.
   (i) The following additional information must appear on the label for blood and blood components intended for autologous transfusion:
      (1) Information adequately identifying the patient, e.g., name, date of birth, hospital, and identification number.
      (2) Date of donation.
      (3) The statement: “AUTOLOGOUS DONOR.”
   (4) The ABO and Rh blood group and type, except as provided in paragraph (c)(9) of this section.
(5) Each container of blood and blood component intended for autologous use and obtained from a donor who fails to meet any of the donor suitability requirements under §640.3 of this chapter or who is reactive to or positive for one or more tests for evidence of infection due to communicable disease agents under §610.40 of this chapter must be prominently and permanently labeled “FOR AUTOLOGOUS USE ONLY” and as otherwise required under §610.40 of this chapter. Such units also may have the ABO and Rh blood group and type on the label.
(6) Units of blood and blood components originally intended for autologous use, except those labeled as prescribed under paragraph (i)(5) of this section, may be issued for allogeneic use and obtained from a donor who fails to meet any of the donor suitability requirements under §640.3 of this chapter or who is reactive to or positive for one or more tests for evidence of infection due to communicable disease agents under §610.40 of this chapter. Such units also may have the ABO and Rh blood group and type on the label.

§ 606.122 Circular of information.

A circular of information must be available for distribution if the product is intended for transfusion. The circular of information must provide adequate directions for use, including the following information:

(a) Instructions to mix the product before use.
(b) Instructions to use a filter in the administration equipment.
(c) The statement “Do Not Add Medications” or an explanation concerning allowable additives.
(d) A description of the product, its source, and preparation, including the name and proportion of the anticoagulant used in collecting the Whole Blood from each product is prepared.
(e) A statement that the product was prepared from blood that was found negative when tested for communicable disease agents, as required under §610.40 of this chapter (include each test that was performed).
(f) The statement: “Warning: The risk of transmitting infectious agents is present. Careful donor selection and available laboratory tests do not eliminate the hazard.”
(g) The names of cryoprotective agents and other additives that may still be present in the product.
(h) The names and results of all tests performed when necessary for safe and effective use.
(i) The use of the product, indications, contraindications, side effects and hazards, dosage and administration recommendations.
(j) [Reserved]
(k) For Red Blood Cells, the circular of information must contain:
   (1) Instructions to administer a suitable plasma volume expander if Red Blood Cells are substituted when Whole Blood is the indicated product.
(l) For Platelets, the circular of information must contain:
   (1) The approximate volume of plasma from which a sample unit of Platelets is prepared.
   (2) Instructions to begin administration as soon as possible, but not more than 4 hours after entering the container.
(m) For Plasma, the circular of information must contain:
   (1) A warning against further processing of the frozen product if there is evidence of breakage or thawing.
(2) Instructions to thaw the frozen product at a temperature appropriate for the product.

(3) When applicable, instructions to begin administration of the product within a specified time after thawing.

(4) Instructions to administer to ABO-group-compatible recipients.

(5) A statement that this product has the same risk of transmitting infectious agents as Whole Blood; other plasma volume expanders without this risk are available for treating hypovolemia.

(n) For Cryoprecipitated AHF, the circular of information must contain:

(1) A statement that the average potency is 80 or more International Units of antihemophilic factor.

(2) The statement: “Usually contains at least 150 milligrams of fibrinogen”; or, alternatively, the average fibrinogen level determined by assay of representative units.

(3) A warning against further processing of the product if there is evidence of breakage or thawing.

(4) Instructions to thaw the product for no more than 15 minutes at a temperature of between 30 and 37 °C.

(5) Instructions to store at room temperature after thawing and to begin administration as soon as possible but no more than 4 hours after entering the container or after pooling and within 6 hours after thawing.

(6) A statement that 0.9 percent Sodium Chloride Injection U.S.P. is the preferred diluent.

(7) Adequate instructions for pooling to ensure complete removal of all concentrated material from each container.

(8) The statement: “Good patient management requires monitoring responses to Cryoprecipitated AHF transfusions with periodic plasma factor VIII or fibrinogen assays in hemophilia A and hypofibrinogenemic recipients, respectively.”


Subpart H—Laboratory Controls

§ 606.140 Laboratory controls.

Laboratory control procedures shall include:

(a) The establishment of scientifically sound and appropriate specifications, standards and test procedures to assure that blood and blood components are safe, pure, potent and effective.

(b) Adequate provisions for monitoring the reliability, accuracy, precision and performance of laboratory test procedures and instruments.

(c) Adequate identification and handling of all test samples so that they are accurately related to the specific unit of product being tested, or to its donor, or to the specific recipient, where applicable.

§ 606.151 Compatibility testing.

Standard operating procedures for compatibility testing shall include the following:

(a) A method of collecting and identifying the blood samples of recipients to ensure positive identification.

(b) The use of fresh recipient serum or plasma samples less than 3 days old for all pretransfusion testing if the recipient has been pregnant or transfused within the previous 3 months.

(c) Procedures to demonstrate incompatibility between the donor’s cell type and the recipient’s serum or plasma type.

(d) A provision that, if the unit of donor’s blood has not been screened by a method that will demonstrate agglutinating, coating and hemolytic antibodies, the recipient’s cells shall be tested with the donor’s serum (minor crossmatch) by a method that will so demonstrate.

(e) Procedures to expedite transfusion in life-threatening emergencies. Records of all such incidents shall be maintained, including complete documentation justifying the emergency action, which shall be signed by a physician.